Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
94 participants
OBSERVATIONAL
2013-08-31
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To enable more effective treatment of uveitic glaucoma, the investigators need to understand more clearly the mechanisms which underlie this process. The investigators therefore propose a study to examine the contribution of altered aqueous dynamics to the development of raised IOP in uveitis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Factors Affecting Aqueous Humor Outflow Facility in Patients with Uveitis
NCT02613442
Severe Intraocular Infection
NCT02818062
Targeted PCR and Acute Endophthalmitis
NCT02850653
Advanced Glaucoma Progression Study
NCT01742819
Study of OCT Peripapillary Angiography in Patients With Advanced Glaucoma
NCT06274593
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Methods
Study Design A cross sectional observational study
Patient Selection All subjects attending the uveitis and glaucoma clinics at St Thomas' Hospital will be eligible to be included in the study if they fulfil the inclusion/exclusion criteria as below.
30 patients will be included from each of these three group of patients: 1) recurrent (\> 5 attacks) idiopathic acute anterior uveitic with raised intraocular pressure; 2) recurrent (\> 5 attacks) idiopathic acute anterior uveitic without raised intraocular pressure; 3) healthy age matched volunteers as controls. Patients on glaucoma treatment will be washed out for one month before measurement.
Examination Schedule and Methods
1. Visual acuity:
Visual acuity is measured before pupil dilation, tonometry, gonioscopy, or any other technique that could affect vision. Two different techniques are used to measure visual acuity, including Snellen and ETDRS visual acuity testing. Refraction is performed prior to formal measurement of visual acuity by either technique.
Subjective Refraction:
It is permissible to use a phoropter or trial frame to determine best-corrected Snellen visual acuity. The left eye is occluded first. An approximate beginning refraction may be determined by retinoscopy, automated refraction, or a subjective refraction from a prior visit. The sphere is refined first. The cylinder is then refined, first the axis followed by the power. Finally, the sphere is rechecked. The right eye is then occluded, and the procedure is repeated for the left eye.
If the patient wears contact lenses and has glasses also, he or she is instructed not to wear the contact lenses on the day of the assessment. Patients unwilling to discontinue contact lens use after surgery will be excluded from the study. In the event that the patient either has no glasses or has forgotten the instructions and reported for the assessment wearing contact lenses, the contact lenses are removed and at least thirty minutes allowed to elapse before subjective refraction and visual acuity testing is performed.
ETDRS Visual Acuity:
The logmar visual acuity testing for the Uveitic Glaucoma study has been adapted from the Early Treatment of Diabetic Retinopathy (ETDRS) at 4 metres. The logmar visual acuity scale facilitates statistical analysis and simplifies quantification of acuity at various distances. The right eye is tested with ETDRS logmar chart 1, then the left eye is tested with ETDRS logmar chart 2. Each chart is hidden from view until the eye being examined is ready for testing.
Snellen Visual Acuity:
Snellen visual acuity may be measured using any standard visual acuity chart. The same type of chart must be used throughout the duration of the study. Standardized refraction is performed prior to Snellen visual acuity testing.
2. Slit lamp biomicroscopy Examination of the anterior segment using slit lamp biomicroscopy will be performed. Slit lamp biomicroscopy may be performed with any commercially available instrument, and it is used in a standard fashion starting anteriorly and working posteriorly.
3. Gonioscopy Gonioscopy is performed with the patient sitting at the slit lamp using either a Zeiss type four-mirror gonioprism or Goldmann single- or three-mirror lens.
4. Pachymetry Central corneal thickness is measured with ultrasound pachymetry. The right eye is tested first. A drop of 0.5% proparacaine is instilled for anesthesia. The patient is asked to look straight ahead at a distant object or fixation target. The pachymeter probe is lined up with the center of the pupil and slowly advanced until it contacts the cornea. The probe is withdrawn when an audible signal is made indicating that a measurement has been recorded. The patient is instructed to blink. The procedure is repeated to obtain three separate readings, and the investigator records the measurements. After testing of the right eye is complete, the same technique is applied to testing of the left eye.
5. Biometry A Carl Zeiss IOL Master will be used to carry out biometry and assess anterior chamber depth using A-scan ultrasound. This is a non-contact examination technique.
6. Fundoscopy A dilated fundus examination is performed. After pupil dilation with appropriate mydriatics, the optic nerve and posterior pole are examined at the slit lamp using Volk 90 diopter, 78 diopter, or 60 diopter lens.
7. Flurophotometry The night before (10 PM) the fluorophotometric scans, participants will self-administered 3 to 6 drops of fluorescein sodium 2% (Minims, Bausch\&Lomb, UK) topically into both eyes at 5 minutes interval depending on their age (age 25 years or younger, 5-6 drops; age 26 to 35 years, four drops; over 35 years of age, three drops). Fluorophotometry will be performed in both eyes using a scanning ocular fluorophotometer from 9AM to 12PM (FM-2, Fluorotron Master Ocular Fluorophotometer; OcuMetrics, Mountain View, California). The aqueous turnover protocol will be used to calculate the aqueous flow rate. Duplicate or triplicate scans will be collected and repeated at 1 hour intervals for 4 measurements to determine the aqueous flow rate (Ft). Following each set of scans, IOP will be measured using pneumatonometry (Model 30 Classic, Reichert Ophthalmic Instruments, Depew, New York). IOP will be recorded as the arithmetic mean of a total of 12 measurements per eye: 3 measurements every hour alternating between eyes.
8. Tonography Tonographic outflow facility (C) will be performed using an electronic Schiøtz tonographer (Model 720, Berkeley Bioengineering Inc, USA) at 10AM. The facility of outflow will be calculated from the rate of decay of intraocular pressure in the supine position during application of a recording Schiøtz tonometer over a period of 4 minutes with a standard 5.5 gram weight. The "R" values of the curve at every 30-second time point will be manually entered into the McLaren tonography computer program. The program fits a second-degree polynomial by least squares to the nine data points and determines the best-fit values for time 0 and time 4 minutes by extrapolation.
Uveoscleral outflow will be calculated using the Goldmann's equation with an assumed episcleral venous of 8, 9, 10 or 11 mmHg. Ft is the rate of aqueous humor formation, C is the tonographic facility of outflow, IOP is the intraocular pressure, Pv is the episcleral venous pressure and Fu is the uveoscleral outflow.
Ft = C (IOP-Pv) +Fu Fu = Ft-C (IOP-Pv)
Only one randomly (Excel random number generator) chosen eye per participant will be included in the data analysis when both eyes fulfilled the inclusion criteria.
9. Visual fields Quantitative automated perimetry is performed using the Humphrey Field Analyzer. Visual field testing is performed before tonometry, gonioscopy, or any other technique that could affect vision. A visual field should be attempted in any eye that has sufficient vision to permit finger counting at two feet. Eyes with poor central vision may have an intact, off-center island of vision which may be measured with perimetry.
A 24-2 threshold test is performed in all patients using a size III white stimulus. Visual field testing may be performed with the Swedish Interactive Thresholding Algorithm (SITA) or full threshold strategy, but the same testing strategy must be used throughout the duration of the study. The pupil diameter should be 3 mm or greater before visual field testing is undertaken, and this may require pharmacologic dilation. Standardized refraction is performed to determine the patient's distance refraction and best-corrected visual acuity prior to visual field testing. The age appropriate plus lens is added to the distance refraction. Patient education is provided, and the instrument is set up for the test. The technician should monitor the patient during testing. Visual fields are performed preoperatively (within one month of enrollment in the study) and annually thereafter. Copies of all visual fields are faxed to the Statistical Coordinating Center for evaluation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy volunteers
healthy age matched with cases volunteers as controls
No interventions assigned to this group
Uveitis with raised IOP
Recurrent (\> 5 attacks) idiopathic acute anterior uveitic with raised intraocular pressure
No interventions assigned to this group
Uveitis with with normal IOP
Recurrent (\> 5 attacks) idiopathic acute anterior uveitic with normal intraocular pressure
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Normal healthy subjects with no ocular problems (other than refractive error) and IOP at screening \< 21mmHg.
3. Age \>18 years.
4. Adequate cognitive function and ability to understand verbal and written information in English.
Exclusion Criteria
2. Normotensive glaucoma.
3. Primary angle closure.
4. Ocular trauma.
5. Intraocular or keratorefractive surgery.
6. Use of systemic medication that may affect aqueous humour production such as beta-blockers.
7. A history of allergy or hypersensitivity to fluorescein.
8. Any abnormalities preventing reliable IOP or fluorophotometric readings.
18 Years
90 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guy's and St Thomas' NHS Foundation Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
K Sheng l, MD
Role: PRINCIPAL_INVESTIGATOR
Guy's and St Thomas NHS Foundation Trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guys and St Thomas NHS Foundation Trust
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ho H, Daas A, Ho J, Alaghband P, Galvis EA, de Antonio Ramirez A, Grassi P, Lim R, Lim KS. Intraocular pressure changes following topical ocular hypotensive medications washout. Br J Ophthalmol. 2021 Feb;105(2):205-209. doi: 10.1136/bjophthalmol-2019-315778. Epub 2020 Apr 10.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
136787
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.